AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback

Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.

Genmab and AbbVie (ABBV) recently clarified that the U.S. portion of the Phase 3 EPCORE DLBCL-1 trial for epcoritamab did not meet its overall survival primary endpoint, raising fresh questions about the drug’s long term commercial potential.

See our latest analysis for AbbVie.

Against this backdrop, AbbVie’s share price has had a strong run, with a 30-day share price return of 10.42% and a 90-day share price return of 30.52%. Its 1-year total shareholder return of 40.53% highlights momentum that has extended over multiple years.

If this kind of momentum has you looking beyond a single pharma stock, it could be a good moment to see what else stands out among 39 healthcare AI stocks.

AbbVie’s business breadth and cash generation give it clear heft, yet the stock has already run hard in recent months. After that kind of move, how much of the quality is already in the price?

Most Popular Narrative: 2.8% Undervalued

On the most followed narrative, AbbVie’s fair value of $266.89 sits only modestly above the last close at $259.36. This puts the focus firmly on execution rather than a huge valuation gap.

AbbVie”s diversified and expanding late-stage and early-stage pipeline, coupled with consistent business development activity (e.g., Capstan in vivo CAR-T, Gubra amylin analog for obesity, next-gen siRNA platforms), positions the company to capitalize on the increasing adoption of biologics and specialty pharmaceuticals, which can reinforce premium pricing and protect net margins.

Read the complete narrative.

Curious what kind of revenue trajectory and profit margins are built into that fair value, and why the assumed future earnings multiple sits well above many pharma peers? The full narrative lays out the earnings path and valuation bridge that analysts are using to justify the current target.

Result: Fair Value of $266.89 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, AbbVie’s story still depends on execution, with patent pressure on key immunology drugs and higher R&D and acquisition spending both capable of unsettling this narrative.

Find out about the key risks to this AbbVie narrative.

Another View: AbbVie’s Rich P/E Tells A Different Story

The earlier narrative leans on a detailed cash flow based view, but AbbVie’s current P/E of 127.5x against a US Biotechs industry average of 16.9x and a fair ratio of 42.8x presents a very different picture of what is already priced in. How comfortable are you paying that kind of premium?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on AbbVie clearly split, this is a moment to move quickly, review the full picture, and weigh both risks and potential rewards, starting with the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond AbbVie?

If AbbVie has sharpened your focus, do not stop here. Broaden your watchlist with focused stock ideas that could sharpen your next move.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ABBV.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com